International Stem Cell Corporation reports $2.4 million product revenue for Q3 2025
International Stem Cell Corporation reported product sales of $2.4 million for the three months ended September 30, 2025, up 9% from $2.2 million in the same period in 2024. For the nine months ended September 30, 2025, product sales were $6.9 million compared to $6.6 million for the prior year period. Net income for the quarter was $57 thousand, compared to a net loss of $125 thousand in the same quarter last year. The increase in product sales was attributed to growth in the Biomedical market segment, particularly from cells and other product sales, partially offset by decreases in media product sales and in the skin care product line. The company reported no revenue generated from its principal therapeutic and clinical product development operations during the period.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. International Stem Cell Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-280090), on November 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.